Nephros Inc (NEPH) - Net Assets
Based on the latest financial reports, Nephros Inc (NEPH) has net assets worth $10.20 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.64 Million) and total liabilities ($3.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Nephros Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.20 Million |
| % of Total Assets | 74.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | -30.83% |
| 10-Year Change | 1429.54% |
| Growth Volatility | 246.54 |
Nephros Inc - Net Assets Trend (2001–2025)
This chart illustrates how Nephros Inc's net assets have evolved over time, based on quarterly financial data. Also explore NEPH total assets for the complete picture of this company's asset base.
Annual Net Assets for Nephros Inc (2001–2025)
The table below shows the annual net assets of Nephros Inc from 2001 to 2025. For live valuation and market cap data, see NEPH company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.20 Million | +18.84% |
| 2024-12-31 | $8.59 Million | +2.72% |
| 2023-12-31 | $8.36 Million | -5.89% |
| 2022-12-31 | $8.88 Million | -39.79% |
| 2021-12-31 | $14.75 Million | -5.29% |
| 2020-12-31 | $15.57 Million | +102.54% |
| 2019-12-31 | $7.69 Million | +13.11% |
| 2018-12-31 | $6.80 Million | +248.62% |
| 2017-12-31 | $1.95 Million | +192.35% |
| 2016-12-31 | $667.00K | -74.96% |
| 2015-12-31 | $2.66 Million | +146.89% |
| 2014-12-31 | $-5.68 Million | -831.31% |
| 2013-12-31 | $-610.00K | -2.52% |
| 2012-12-31 | $-595.00K | -141.87% |
| 2011-12-31 | $1.42 Million | +952.59% |
| 2010-12-31 | $135.00K | -93.11% |
| 2009-12-31 | $1.96 Million | -22.73% |
| 2008-12-31 | $2.53 Million | -71.06% |
| 2007-12-31 | $8.76 Million | +517.71% |
| 2006-12-31 | $-2.10 Million | -138.97% |
| 2005-12-31 | $5.38 Million | -44.26% |
| 2004-12-31 | $9.65 Million | +279.30% |
| 2003-12-31 | $-5.38 Million | +32.68% |
| 2002-12-31 | $-8.00 Million | -386.92% |
| 2001-12-31 | $-1.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nephros Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12812130700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.11% |
| Other Components | $153.33 Million | 1502.93% |
| Total Equity | $10.20 Million | 100.00% |
Nephros Inc Competitors by Market Cap
The table below lists competitors of Nephros Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XPLUS SA ZY -01
F:75R
|
$33.06 Million |
|
Grace Therapeutics, Inc.
NASDAQ:GRCE
|
$33.06 Million |
|
Ashima Limited
NSE:ASHIMASYN
|
$33.08 Million |
|
Zanaga Iron Ore Company Limited
F:6ZA
|
$33.09 Million |
|
OneMedNet Corp.
NASDAQ:ONMD
|
$33.05 Million |
|
Memscap Regpt
PA:MEMS
|
$33.02 Million |
|
Bukit Darmo Property Tbk
JK:BKDP
|
$33.02 Million |
|
Big 5 Sporting Goods Corporation
NASDAQ:BGFV
|
$33.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nephros Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,585,000 to 10,202,000, a change of 1,617,000 (18.8%).
- Net income of 1,194,000 contributed positively to equity growth.
- Other factors increased equity by 423,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.19 Million | +11.7% |
| Other Changes | $423.00K | +4.15% |
| Total Change | $- | 18.84% |
Book Value vs Market Value Analysis
This analysis compares Nephros Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $-903.11 | $3.11 | x |
| 2003-12-31 | $-607.97 | $3.11 | x |
| 2004-12-31 | $393.71 | $3.11 | x |
| 2005-12-31 | $78.92 | $3.11 | x |
| 2006-12-31 | $-30.63 | $3.11 | x |
| 2007-12-31 | $100.73 | $3.11 | x |
| 2008-12-31 | $11.95 | $3.11 | x |
| 2009-12-31 | $9.22 | $3.11 | x |
| 2010-12-31 | $0.58 | $3.11 | x |
| 2011-12-31 | $1.48 | $3.11 | x |
| 2012-12-31 | $-0.48 | $3.11 | x |
| 2013-12-31 | $-0.26 | $3.11 | x |
| 2014-12-31 | $-2.15 | $3.11 | x |
| 2015-12-31 | $0.69 | $3.11 | x |
| 2016-12-31 | $0.12 | $3.11 | x |
| 2017-12-31 | $0.33 | $3.11 | x |
| 2018-12-31 | $0.55 | $3.11 | x |
| 2019-12-31 | $0.62 | $3.11 | x |
| 2020-12-31 | $1.38 | $3.11 | x |
| 2021-12-31 | $1.17 | $3.11 | x |
| 2022-12-31 | $0.54 | $3.11 | x |
| 2023-12-31 | $0.80 | $3.11 | x |
| 2024-12-31 | $0.81 | $3.11 | x |
| 2025-12-31 | $0.93 | $3.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nephros Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.70%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.35%
- • Asset Turnover: 1.38x
- • Equity Multiplier: 1.34x
- Recent ROE (11.70%) is above the historical average (-142.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.62 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.10 Million |
| 2004 | -78.71% | -5488.55% | 0.01x | 1.26x | $-8.56 Million |
| 2005 | -101.65% | -225.54% | 0.31x | 1.45x | $-6.01 Million |
| 2006 | 0.00% | -1009.83% | 0.15x | 0.00x | $-7.80 Million |
| 2007 | -301.01% | -2203.68% | 0.12x | 1.15x | $-27.23 Million |
| 2008 | -250.08% | -430.21% | 0.36x | 1.59x | $-6.59 Million |
| 2009 | -103.47% | -76.14% | 1.00x | 1.35x | $-2.22 Million |
| 2010 | -1431.85% | -65.79% | 1.85x | 11.78x | $-1.95 Million |
| 2011 | -166.08% | -106.59% | 0.55x | 2.81x | $-2.50 Million |
| 2012 | 0.00% | -180.52% | 0.51x | 0.00x | $-3.20 Million |
| 2013 | 0.00% | -212.53% | 0.60x | 0.00x | $-3.64 Million |
| 2014 | 0.00% | -421.68% | 0.52x | 0.00x | $-6.80 Million |
| 2015 | -115.92% | -158.85% | 0.49x | 1.49x | $-3.35 Million |
| 2016 | -454.57% | -130.69% | 0.87x | 4.01x | $-3.10 Million |
| 2017 | -41.49% | -21.24% | 0.76x | 2.56x | $-1.00 Million |
| 2018 | -89.57% | -59.82% | 0.54x | 2.78x | $-3.78 Million |
| 2019 | -73.16% | -33.09% | 0.89x | 2.49x | $-3.89 Million |
| 2020 | -38.06% | -55.67% | 0.46x | 1.48x | $-6.02 Million |
| 2021 | -35.12% | -40.20% | 0.58x | 1.51x | $-5.28 Million |
| 2022 | -132.01% | -74.01% | 0.91x | 1.97x | $-7.94 Million |
| 2023 | -18.84% | -11.06% | 1.20x | 1.42x | $-2.41 Million |
| 2024 | 0.86% | 0.52% | 1.26x | 1.31x | $-784.50K |
| 2025 | 11.70% | 6.35% | 1.38x | 1.34x | $173.80K |
Industry Comparison
This section compares Nephros Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,863,507,886
- Average return on equity (ROE) among peers: -17.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nephros Inc (NEPH) | $10.20 Million | 0.00% | 0.34x | $33.05 Million |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $64.44 Million |
| Align Technology Inc (ALGN) | $1.35 Billion | 32.89% | 0.86x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $517.03 Million | -1.36% | 0.37x | $444.32 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $16.74 Million | -22.66% | 1.01x | $1.44 Billion |
| Avinger Inc (AVGR) | $-73.64 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $10.52 Million | -163.15% | 1.04x | $156.14 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $5.43 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $7.87 Billion | 19.65% | 1.00x | $8.85 Billion |
About Nephros Inc
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and p… Read more